Stoke Therapeutics (NASDAQ:STOK) said its Phase III EMPEROR study of zorevunersen for Dravet syndrome has enrolled 162 patients, exceeding its target enrollment of 150, with no patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results